Patent Analysis
Patent Analysis
Sale
The cancer diagnostics market was valued at USD 61.50 billion in 2023. It is expected to grow at a CAGR of 13.6% during the forecast period of 2024-2032 and attain a market value of USD 194.54 billion in 2032. The market value is impacted by the increasing use of such platforms and ongoing technological advancements in this field. There has been a significant increase in number of patent applications associated with cancer diagnostics, driven by increasing global incidence of cancer requires advanced diagnostic tools for early detection and treatment planning.
The global cancer diagnostics patent landscape report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for global cancer diagnostics include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within cancer diagnostic technologies.
Flow cytometry, a powerful technique used in cancer diagnosis to analyze the physical and chemical properties of cells or particles. Using fluorescently labeled antibodies, it can identify and quantify specific cell populations, detect abnormal cell markers, and assess cell health, which is critical for diagnosing hematologic cancers such as leukemia and lymphoma. This method provides fast, accurate and detailed information about cancer cells, which helps in effective diagnosis and treatment. Therefore, such technical innovations are impacting the patent landscape significantly.
Cancer diagnostics refers to tools, materials, and equipment used in medical laboratories and clinical settings to detect, analyze, and monitor cancer. These include a wide range of products such as reagents, analysis kits, testing equipment, imaging systems (such as MRI and CT scanners), molecular diagnostic tools (such as PCR machines) and specialty equipment (such as flow cytometers and digital pathology scanners). These consumables and instruments are essential for performing various tests, analyzes and imaging studies to diagnose cancer, determine its stage, guide treatment decisions, and monitor the effectiveness of treatment and the progression of the disease over time.
Cancer diagnostics continues to evolve, driven by the growing healthcare expenditure, especially in developing economies, and supports the adoption of advanced diagnostic technologies. Large investments in research and development activities by pharmaceutical and biotechnology companies are leading to the development of new and better diagnostic products. Cooperation between diagnostic companies and research institutes enabling the development and marketing of innovative diagnostic tools, which is a driving factor to boost market value in the forecast period.
Increasing Technological Innovation in Cancer Diagnosis is Expected to Augment the Market Growth
Technological innovations in cancer diagnosis include advances such as next-generation sequencing (NGS), digital pathology and the integration of artificial intelligence. These innovations increase the accuracy and efficiency of cancer detection, enable personalized treatment strategies and facilitate real-time monitoring of disease progression, improving patient outcomes and fueling market growth.
For instance, In June 2022, F. Hoffmann-La Roche Ltd announced the launch of its BenchMark ULTRA PLUS System (including hardware, software and assays) which is an advanced tissue staining platform. The system enables fast and accurate test results so that doctors can make timely decisions about the patient's treatment for cancer.
Rising Demand for Personalized Medicine is Expected to Propel the Cancer Diagnostics Industry Growth
The growing demand for personalized medicine in cancer care is driving the introduction of advanced diagnostic instruments and accessories. These tools enable comprehensive genomic profiling and molecular diagnostics to help oncologists tailor treatment to individual patient characteristics, improving treatment efficacy and patient outcomes and accelerating market expansion.
The report provides an in-depth analysis of the patents in this field by the following segmentation -
Breakup by Product
Breakup by Technology
The breakup based on technology includes positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), multi-parameter flow cytometry, immunohistochemistry, microarray and next generation sequencing (NGS). Cancer diagnostic investigations have been conducted with the chosen patent families labelled based on the technologies to which they pertain.
Positron emission tomography (PET) is an advanced imaging technique used in cancer diagnosis to visualize and evaluate the metabolic activity of tissues. PET scans contain small amounts of a radioactive tracer that accumulates in areas of high metabolic activity, such as tumors. By identifying these areas, PET scans can help diagnose cancer, determine its stage, assess response to therapy and monitor disease recurrence. This non-invasive imaging plays a vital role in oncology, providing detailed information about the biological behaviour of tumours, aiding treatment planning and improving patient care.
Detailed technological data will be provided for all specified segments classified in this report.
The United States is one of the leading jurisdictions for cancer diagnostics patents, having around 310,000 patents. The presence of a well-established healthcare infrastructure, a robust legal framework and prominent research institutions engaged in innovations contributes to the patent landscape significantly.
Holding a substantial portion of the global population, China is another vital jurisdiction and is witnessing rapid growth in patent filings. The expanding healthcare landscape in the region contributes to the evolving research capabilities, thereby influencing a surge in patent applications. Innovations like development of novel contrast agents and imaging probes is amongst major growth factors.
Among the players with Cancer Diagnostics patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:
F. Hoffmann-La Roche Ltd
Often referred to as Roche, this multinational healthcare corporation with its headquarters located in Basel, Switzerland focuses on pharmaceuticals and diagnostics. Leading the way in cancer diagnostics, Roche provides cutting-edge methods for early and precise cancer detection, including liquid and tissue biopsies and sophisticated molecular testing. The company's broad portfolio and dedication to personalized medicine greatly improve patient outcomes and cancer treatment.
Abbott
A major global healthcare company specializing in diagnostics, medical devices, nutrition and generics. In cancer diagnosis, Abbott offers a variety of products, including molecular assays and companion diagnostics, that support personalized medicine approaches. The company's innovative technologies improve cancer detection, treatment monitoring and patient outcomes worldwide.
Other companies include GE HealthCare Technologies, Inc., Qiagen N.V., and Becton Dickinson & Company among others.
The global cancer diagnostics patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by:
Scope of the Report | Details |
Analysis by Product |
|
Key Players Mentioned |
|
Geographies Covered |
|
Global Ovarian Cancer Diagnostics and Therapeutics Market
Global Companion Diagnostics Market
Global Diagnostic Imaging Services Market
Global Pont-Of-Care (POC) Diagnostic Market
Global In-Vitro Diagnostics Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Introduction
2 Executive Summary
3 Global Cancer Diagnostics Market Overview
3.1 Global Cancer Diagnostics Market Historical Value (2017-2023)
3.2 Global Cancer Diagnostics Market Forecast Value (2024-2032)
4 Global Cancer Diagnostics Market Segmentation
4.1 Global Cancer Diagnostics Market Share by Product
4.1.1 Market Overview
4.1.2 Consumables
4.1.2.1 Antibodies
4.1.2.2 Reagents
4.1.2.3 Probes
4.1.2.4 Others
4.1.3 Instrument
4.1.3.1 Pathology Instrument
4.1.3.2 Imaging Instrument
4.1.3.3 Others
4.2 Global Cancer Diagnostics Market Share by Indication
4.2.1 Market Overview
4.2.2 Breast Cancer
4.2.3 Lung Cancer
4.2.4 Colorectal Cancer
4.2.5 Brain Tumor
4.2.6 Blood Cancer
4.2.7 Others
4.3 Global Cancer Diagnostics Market Share by End User
4.3.1 Market Overview
4.3.2 Hospital
4.3.3 Diagnostic Laboratory
4.3.4 Research Centre
5 Global Market Dynamics
5.1 Market Drivers and Constraints
5.2 Porter’s Five Forces Analysis
5.3 PESTEL Analysis
5.4 Industry Events, Initiatives, and Trends
5.5 Value Chain Analysis
6 Global Cancer Diagnostics Patent Landscape Analysis
6.1 Patent Distribution by Publication Year
6.2 Patent Distribution by Application Year
6.3 Patent Distribution by Priority Year
6.4 Analysis by Type of Patent
6.4.1 Granted Patents
6.4.2 Patent Application
6.4.3 Amended Application
6.4.4 Search Report
6.5 Analysis by Legal Status
6.5.1 Active
6.5.2 Pending
6.5.3 Expired/Discontinued
6.6 Analysis by Patent Jurisdiction
6.7 Analysis by Patent Age
6.8 Analysis by Cooperative Patent Classification (CPC) Codes
6.9 Average Time to Publish a Patent
6.9.1 By Entities
6.9.2 By Jurisdiction
6.9.3 By Technology
6.10 Analysis by Type of Entity (Academic and Non-Academic)
6.11 Analysis by Top Applicants
6.12 Analysis by Top Inventors
7 Global Cancer Diagnostics Patent Analysis by Technology
7.1 Total Patents by Top Technologies
7.2 Time Evolution of Patents by Technology
7.3 Emerging Technologies
7.4 Medical imaging
7.4.1 Time Evolution by Number of Patents
7.4.2 Time Evolution by Number of Patent Families
7.4.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.4.4 Analysis by Top Applicants
7.4.5 Analysis by Top Inventors
7.5 AI-based tool
7.5.1 Time Evolution by Number of Patents
7.5.2 Time Evolution by Number of Patent Families
7.5.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.5.4 Analysis by Top Applicants
7.5.5 Analysis by Top Inventors
7.6 Lab-on-chip
7.6.1 Time Evolution by Number of Patents
7.6.2 Time Evolution by Number of Patent Families
7.6.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.6.4 Analysis by Top Applicants
7.6.5 Analysis by Top Inventors
7.7 Liquid biopsy
7.7.1 Time Evolution by Number of Patents
7.7.2 Time Evolution by Number of Patent Families
7.7.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.7.4 Analysis by Top Applicants
7.7.5 Analysis by Top Inventors
*Complete technology list will be provided in the report.
8 EMR Patent Valuation Analysis
8.1 Assessment Methodology
8.2 High Value Patents
8.3 Medium Value Patents
8.4 Low Value Patents
9 Global Cancer Diagnostics – Top 10 Players Patent Analysis
9.1 Top 10 Entities by Number of Patents
9.2 Analysis by Publication Year
9.3 Analysis by Application Year
9.4 Analysis by Priority Year
9.5 Analysis by Type of Patent
9.6 Analysis by Jurisdiction
9.7 Analysis by Cooperative Patent Classification (CPC) Codes
9.8 Analysis by Source of Innovation
9.9 Analysis by Forward and Backward Citations
9.10 Analysis by Legal Status
9.11 Analysis by Patent Age
9.12 Analysis by Key Inventors
9.13 Entity Dynamics
9.13.1 Analysis by Type of Player (Academic vs Non-Academic)
9.13.2 Analysis by Collaboration
9.13.3 Analysis by Technology
9.13.4 Newcomers
9.13.4.1 Start-up Companies
9.13.4.2 Established Companies
10 Patent Profile of Key Players
10.1 GE HealthCare Technologies, Inc .
10.1.1 Product Portfolio
10.1.2 Patent Portfolio by Patent Families
10.1.3 Time Evolution of Patents
10.1.4 Geographical Patent Coverage
10.1.5 Patent Analysis by Technology
10.1.6 Patent News and Developments
10.1.7 Financial Analysis
10.1.8 SWOT Analysis
10.2 Abbott Laboratories
10.3 F. Hoffmann-La Roche Ltd
10.4 Qiagen N.V .
10.5 Becton Dickinson & Company
11 Future Trends
12 Global Cancer Diagnostics Market Landscape (Additional Insight)*
12.1 Global Cancer Diagnostics: Developers Landscape
12.1.1 Analysis by Year of Establishment
12.1.2 Analysis by Company Size
12.1.3 Analysis by Region
12.2 Global Cancer Diagnostics: Product Landscape
12.2.1 Analysis by Product Type
12.2.2 Analysis by Technology
12.2.3 Analysis by Application
*Additional insights are not provided in the standard report.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.